Christophe Vidonne and Dr. Ralph Billo about Novartis' Buffer Management Concept


"From an end-to-end perspective, what really counts is what remains visible and measurable for our customers. It is not only about key performance indicators and delivery service but also the ability to properly communicate accurate and meaningful supply chain information in a multi-cultural and cross-functional environment across geographies."
Christophe Vidonne, Head Supply Chain Management and Dr. Ralph Billo, Head Global Supply Chain Management, Novartis
Novartis Animal Health (NAH) is a leading global provider of solutions for the prevention and treatment of various widespread animal diseases and parasite infestations. To maintain and even strengthen their market position, NAH are eager to continuously improve their supply chain performance as one of the key drivers of the company's success. Therefore, a few years ago NAH triggered a state-of-the-art supply chain planning initiative with a special focus on redesigning their replenishment framework. The main change concerned a transformation from push to pull replenishment for selected products within their portfolio. The successful realization of the benefits of pull replenishment was enabled by the implementation of buffer management as a Lean replenishment mode. This enabled NAH not only to reduce supply chain inventories but also to increase planning accuracy while reducing required planning efforts. These positive impacts underline the benefits of the supply chain initiative and prove that NAH has come a long way towards a truly integrated supply chain.
Learn more about Lean Supply Chain Planning, just visit www.leansupplychainplanning.com.
most read

Arkema Launches Acrylic Acid Purification Project
Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Roche and Zealand Pharma Collaborate on Weight Management Drug
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Novo Nordisk Invests $1.09 Billion in Brazil
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.

Orion Announced Plans to Shut Down Carbon Black Plants
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.

BASF Divests Two Joint Ventures in China
BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.